Loading clinical trials...

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE2

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma

NCT04291885•Melanoma and Skin Cancer Trials Limited

View on ClinicalTrials.gov

Summary

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.

Detailed Description

The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Participants on the trial will receive either avelumab or placebo for 6 months. The primary aim of the I-MAT trial is to develop an effective, well-tolerated adjuvant immunotherapy regimen for patients with stage I-III MCC, post a range of definitive loco-regional treatment options.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Histologically confirmed Merkel cell carcinoma (MCC) which is either:
•* clinical stage I;
•* pathological stage I with positive LVSI only;
•* clinical or pathological stage II (including IIA and IIB);
•* clinical or pathological stage III (including IIIA and IIIB).
•2. Absence of distant metastatic disease on baseline 18-Fludeoxyglucose (18FDG) - Positron Emission Tomography (PET) / Computed Tomography (CT) scan.
•3. 18 years of age or older.
•4. Eastern Cooperative Oncology Group (ECOG) of 0 - 2.
•5. Willing and able to provide written informed consent and comply with all study requirements.
•6. Adequate haematological, liver and renal function as determined by the screening laboratory values outlined in the protocol obtained within 14 days prior to randomisation.
+2 more criteria

Exclusion Criteria

•1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest significant risk for immune-related adverse events.
•2. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.
•3. Previous cancer immunotherapy, specifically interferon, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways are not permitted.
•4. Prior treatment with other immune-modulating agents that was within fewer than 28 days prior to the first dose of Avelumab.
•5. Active infection requiring antibiotics within 7 days of cycle 1 day 1 of study drug dose.
•6. Active tuberculosis.
•7. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
•8. Uncontrolled infection with hepatitis B or hepatitis C virus (HBV or HCV) infection; Patients with previously successfully treated HCV, with positive anti-HCV antibody but undetectable (HCV) ribonucleic acid (RNA) levels are allowed on trial.
•9. Current use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical steroids, or local steroid injection ; b. systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions
•10. Any systemic anti-cancer treatment (chemotherapy, targeted systemic therapy) investigational or standard of care, within 28 days of the first dose of Avelumab or planned to occur during the study period. Patients receiving bisphosphonates or denosumab will not be excluded.
+9 more criteria

Locations (20)

Port Macquarie Base Hospital

Port Macquarie, New South Wales, Australia

Chris O'Brien Lifehouse